"​A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma​​​​."​ Oncologist. 2021 (PubMed)

"Cybersecurity in Science and Medicine: Threats and Challenges." Trends Biotechnol. 2020  (PubMed)

"Kinesin family member 11 is a potential therapeutic target and is suppressed by microRNA-30a in breast cancer." Mol Carcinog. 2020 (PubMed)

"​Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway​." J Biomed Sci. 2019 (PubMed)​

“Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor   Survivability of Breast Cancer.” Journal Oncology 2019. (PubMed)

“Overexpression of ASPM gene is associated with aggressiveness and poor outcome in bladder cancer.” Oncol Lett.
2019. (PubMed)

"FDA Guidance for Next Generation Sequencing-based Testing: Balancing Regulation and Innovation in Precision   Medicine.” Nature Genomic Medicine. 2018 (PubMed)

“Benefits and Harms of the Centers for Medicare & Medicaid Services Ruling on Results From Genome Sequencing.”   JAMA Oncology. 2018 (PubMed)

"Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is   associated with aggressive clinicopathological manifestations of breast cancer.” Am J Transl Res. 2018 (PubMed)

“An integrated bioinformational analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer.”   Onco Targets Ther. 2018 (PubMed)

“A homozygous variant in RRM2B  is associated with severe metabolic acidosis and early neonatal death.” Eur J Med   Genetics. 2018 (PubMed)

“Novel common genetic susceptibility loci for colorectal cancer.” Journal of the National Cancer Institute. 2018   (PubMed)

“Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis". J Breast   Cancer. 2017 (PubMed)

“Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast   cancers.” Carcinogenesis. 2017 (PubMed)

“Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.”   Oncol Report. 2017 (PubMed)

“Preclinical effects of CRLX101, and investigational camptothecin-containing nanoparticle drug conjugate, on treating   glioblastoma multiforme via apoptosis and antiangiogenesis." Oncotarget. 2016 (PubMed)

“Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic   cholangiocarcinoma.” Oncotarget. 2016 (PubMed)



668 Arrow Grand Circle, Suite 101, Covina, CA 91722            Office Phone: (626) 238-9987    

Sino-American Cancer Foundation © 2019  |  All Rights Reserved

Sino American 

​Cancer Foundation